New drug could slash relapse risk in aggressive breast cancer
Disease control
Ongoing
This phase 3 trial tests whether the drug sacituzumab govitecan can prevent breast cancer from coming back in people with HER2-negative breast cancer who still have cancer cells after standard chemotherapy before surgery. About 1,300 participants will receive either the new drug …
Phase: PHASE3 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated May 26, 2026 12:05 UTC